Sun Pharma buys Ranbaxy in $3.2bn all-share deal

Deal will turn Sun Pharma into the world's fifth-largest generic drug company but some analysts doubt it can turn Ranbaxy around.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES